60 Degrees Pharmaceuticals Partners with Runway Health to Expand Access to Malaria Prevention

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has teamed up with Runway Health to make malaria prevention more accessible for international travelers. Starting April 2, 2026, this partnership will provide travelers with pre-departure access to ARAKODA® (tafenoquine), the only FDA-approved, broad-spectrum, once-weekly malaria prevention prescription available in the U.S.

Through Runway Health, travelers can schedule online consultations with U.S.-licensed physicians. If prescribed, the medication will be delivered directly to their homes before their trip. This streamlined process ensures travelers can align their itineraries with personalized treatment plans.

With this collaboration, 60 Degrees Pharmaceuticals and Runway Health aim to simplify malaria prevention and enhance travel safety for those heading to malaria-prone regions.

To find out more investor information about 60 degree Pharmaceuticals please visit www.investors.60degreepharma.com.